Suzetrigine: A novel selective sodium channel inhibitor for pain
Suzetrigine represents an advancement in pain management as a nonopioid alternative for pain with potentially lower abuse risk and potentially fewer serious adverse effects when compared to opioids. While initial results are promising, further research is needed to establish its long-term safety and efficacy for various painful conditions. Research will continue in the area of analgesics that selectivity inhibit peripheral sodium channels.
Authors
- Sudheer Potru (ORCID: https://orcid.org/0000-0002-7081-1154)
- P. Mani Mathew (ORCID: https://orcid.org/0000-0002-6287-9191)
- D. Mark Courtney (ORCID: https://orcid.org/0000-0002-0905-465X)
Institutions
- United States Department of Veterans Affairs (US)
- VA Capitol Health Care Network (US)
- VA Southeast Network (US)
- Atlanta VA Health Care System (US)
Publication Details
- Journal
- American Journal of Health-System Pharmacy
- Published
- 2025-08-15
- DOI
- https://doi.org/10.1093/ajhp/zxaf219
- Primary Topic
- Pain Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00